Modulators of HIF1α and NFkB in cancer treatment: Is it a rational approach for controlling malignant progression?

Marco Tafani, Bruna Pucci, Andrea Russo, Luana Schito, Laura Pellegrini, Giulietta A. Perrone, Lidia Villanova, Luisa Salvatori, Linda Ravenna, Elisa Petrangeli, Matteo A. Russo

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

HIF1α and NFkB are two transcription factors very frequently activated in tumors and involved in tumor growth, progression, and resistance to chemotherapy. In fact, HIF1α and NFkB together regulate transcription of over a thousand genes that, in turn, control vital cellular processes such as adaptation to the hypoxia, metabolic reprograming, inflammatory reparative response, extracellular matrix digestion, migration and invasion, adhesion, etc. Because of this wide involvement they could control in an integrated manner the origin of the malignant phenotype. Interestingly, hypoxia and inflammation have been sequentially bridged in tumors by the discovery that alarmin receptors genes such as RAGE, P2X7, and some TLRs, are activated by HIF1α and that, in turn, alarmin receptors strongly activate NFkB and proinflammatory gene expression, evidencing all the hallmarks of the malignant phenotype. Recently, a large number of drugs have been identified that inhibit one or both transcription factors with promising results in terms of controlling tumor progression. In addition, many of these molecules are natural compounds or off-label drugs already used to cure other pathologies. Some of them are undergoing clinical trials and soon they will be used alone or in combination with standard anti-tumoral agents to achieve a better treatment of tumors with reduction of metastasis formation and, more importantly, with a net increase in survival. This review highlights the central role of HIF1a activated in hypoxic regions of the tumor, of NFkB activation and proinflammatory gene expression in transformed cells to understand their progression toward malignancy. Different molecules and strategies to inhibit these transcription factors will be reviewed. Finally, the central role of a new class of deacetylases called Sirtuins in regulating HIF1a and NFkB activity will be outlined.

Original languageEnglish
Article numberArticle 13
JournalFrontiers in Pharmacology
Volume4 FEB
DOIs
Publication statusPublished - 2013

Fingerprint

Neoplasms
Transcription Factors
Therapeutics
Sirtuins
Phenotype
Gene Expression
Pharmaceutical Preparations
Genes
Extracellular Matrix
Digestion
Clinical Trials
Pathology
Neoplasm Metastasis
Inflammation
Drug Therapy
Growth
Hypoxia
Alarmins

Keywords

  • Cancer
  • HIF1α inhibitors
  • Hypoxia
  • Inflammation
  • NFkB inhibitors
  • Sirtuin activators

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Modulators of HIF1α and NFkB in cancer treatment : Is it a rational approach for controlling malignant progression? / Tafani, Marco; Pucci, Bruna; Russo, Andrea; Schito, Luana; Pellegrini, Laura; Perrone, Giulietta A.; Villanova, Lidia; Salvatori, Luisa; Ravenna, Linda; Petrangeli, Elisa; Russo, Matteo A.

In: Frontiers in Pharmacology, Vol. 4 FEB, Article 13, 2013.

Research output: Contribution to journalArticle

Tafani, M, Pucci, B, Russo, A, Schito, L, Pellegrini, L, Perrone, GA, Villanova, L, Salvatori, L, Ravenna, L, Petrangeli, E & Russo, MA 2013, 'Modulators of HIF1α and NFkB in cancer treatment: Is it a rational approach for controlling malignant progression?', Frontiers in Pharmacology, vol. 4 FEB, Article 13. https://doi.org/10.3389/fphar.2013.00013
Tafani, Marco ; Pucci, Bruna ; Russo, Andrea ; Schito, Luana ; Pellegrini, Laura ; Perrone, Giulietta A. ; Villanova, Lidia ; Salvatori, Luisa ; Ravenna, Linda ; Petrangeli, Elisa ; Russo, Matteo A. / Modulators of HIF1α and NFkB in cancer treatment : Is it a rational approach for controlling malignant progression?. In: Frontiers in Pharmacology. 2013 ; Vol. 4 FEB.
@article{ba185999c2e34a9083b7710d352211a2,
title = "Modulators of HIF1α and NFkB in cancer treatment: Is it a rational approach for controlling malignant progression?",
abstract = "HIF1α and NFkB are two transcription factors very frequently activated in tumors and involved in tumor growth, progression, and resistance to chemotherapy. In fact, HIF1α and NFkB together regulate transcription of over a thousand genes that, in turn, control vital cellular processes such as adaptation to the hypoxia, metabolic reprograming, inflammatory reparative response, extracellular matrix digestion, migration and invasion, adhesion, etc. Because of this wide involvement they could control in an integrated manner the origin of the malignant phenotype. Interestingly, hypoxia and inflammation have been sequentially bridged in tumors by the discovery that alarmin receptors genes such as RAGE, P2X7, and some TLRs, are activated by HIF1α and that, in turn, alarmin receptors strongly activate NFkB and proinflammatory gene expression, evidencing all the hallmarks of the malignant phenotype. Recently, a large number of drugs have been identified that inhibit one or both transcription factors with promising results in terms of controlling tumor progression. In addition, many of these molecules are natural compounds or off-label drugs already used to cure other pathologies. Some of them are undergoing clinical trials and soon they will be used alone or in combination with standard anti-tumoral agents to achieve a better treatment of tumors with reduction of metastasis formation and, more importantly, with a net increase in survival. This review highlights the central role of HIF1a activated in hypoxic regions of the tumor, of NFkB activation and proinflammatory gene expression in transformed cells to understand their progression toward malignancy. Different molecules and strategies to inhibit these transcription factors will be reviewed. Finally, the central role of a new class of deacetylases called Sirtuins in regulating HIF1a and NFkB activity will be outlined.",
keywords = "Cancer, HIF1α inhibitors, Hypoxia, Inflammation, NFkB inhibitors, Sirtuin activators",
author = "Marco Tafani and Bruna Pucci and Andrea Russo and Luana Schito and Laura Pellegrini and Perrone, {Giulietta A.} and Lidia Villanova and Luisa Salvatori and Linda Ravenna and Elisa Petrangeli and Russo, {Matteo A.}",
year = "2013",
doi = "10.3389/fphar.2013.00013",
language = "English",
volume = "4 FEB",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - Modulators of HIF1α and NFkB in cancer treatment

T2 - Is it a rational approach for controlling malignant progression?

AU - Tafani, Marco

AU - Pucci, Bruna

AU - Russo, Andrea

AU - Schito, Luana

AU - Pellegrini, Laura

AU - Perrone, Giulietta A.

AU - Villanova, Lidia

AU - Salvatori, Luisa

AU - Ravenna, Linda

AU - Petrangeli, Elisa

AU - Russo, Matteo A.

PY - 2013

Y1 - 2013

N2 - HIF1α and NFkB are two transcription factors very frequently activated in tumors and involved in tumor growth, progression, and resistance to chemotherapy. In fact, HIF1α and NFkB together regulate transcription of over a thousand genes that, in turn, control vital cellular processes such as adaptation to the hypoxia, metabolic reprograming, inflammatory reparative response, extracellular matrix digestion, migration and invasion, adhesion, etc. Because of this wide involvement they could control in an integrated manner the origin of the malignant phenotype. Interestingly, hypoxia and inflammation have been sequentially bridged in tumors by the discovery that alarmin receptors genes such as RAGE, P2X7, and some TLRs, are activated by HIF1α and that, in turn, alarmin receptors strongly activate NFkB and proinflammatory gene expression, evidencing all the hallmarks of the malignant phenotype. Recently, a large number of drugs have been identified that inhibit one or both transcription factors with promising results in terms of controlling tumor progression. In addition, many of these molecules are natural compounds or off-label drugs already used to cure other pathologies. Some of them are undergoing clinical trials and soon they will be used alone or in combination with standard anti-tumoral agents to achieve a better treatment of tumors with reduction of metastasis formation and, more importantly, with a net increase in survival. This review highlights the central role of HIF1a activated in hypoxic regions of the tumor, of NFkB activation and proinflammatory gene expression in transformed cells to understand their progression toward malignancy. Different molecules and strategies to inhibit these transcription factors will be reviewed. Finally, the central role of a new class of deacetylases called Sirtuins in regulating HIF1a and NFkB activity will be outlined.

AB - HIF1α and NFkB are two transcription factors very frequently activated in tumors and involved in tumor growth, progression, and resistance to chemotherapy. In fact, HIF1α and NFkB together regulate transcription of over a thousand genes that, in turn, control vital cellular processes such as adaptation to the hypoxia, metabolic reprograming, inflammatory reparative response, extracellular matrix digestion, migration and invasion, adhesion, etc. Because of this wide involvement they could control in an integrated manner the origin of the malignant phenotype. Interestingly, hypoxia and inflammation have been sequentially bridged in tumors by the discovery that alarmin receptors genes such as RAGE, P2X7, and some TLRs, are activated by HIF1α and that, in turn, alarmin receptors strongly activate NFkB and proinflammatory gene expression, evidencing all the hallmarks of the malignant phenotype. Recently, a large number of drugs have been identified that inhibit one or both transcription factors with promising results in terms of controlling tumor progression. In addition, many of these molecules are natural compounds or off-label drugs already used to cure other pathologies. Some of them are undergoing clinical trials and soon they will be used alone or in combination with standard anti-tumoral agents to achieve a better treatment of tumors with reduction of metastasis formation and, more importantly, with a net increase in survival. This review highlights the central role of HIF1a activated in hypoxic regions of the tumor, of NFkB activation and proinflammatory gene expression in transformed cells to understand their progression toward malignancy. Different molecules and strategies to inhibit these transcription factors will be reviewed. Finally, the central role of a new class of deacetylases called Sirtuins in regulating HIF1a and NFkB activity will be outlined.

KW - Cancer

KW - HIF1α inhibitors

KW - Hypoxia

KW - Inflammation

KW - NFkB inhibitors

KW - Sirtuin activators

UR - http://www.scopus.com/inward/record.url?scp=84876569908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876569908&partnerID=8YFLogxK

U2 - 10.3389/fphar.2013.00013

DO - 10.3389/fphar.2013.00013

M3 - Article

C2 - 23408731

AN - SCOPUS:84876569908

VL - 4 FEB

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

M1 - Article 13

ER -